SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-277541
Filing Date
2023-11-15
Accepted
2023-11-15 07:30:01
Documents
13
Period of Report
2023-11-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d850558d8k.htm   iXBRL 8-K 27309
  Complete submission text file 0001193125-23-277541.txt   180093

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tcrt-20231114.xsd EX-101.SCH 3210
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tcrt-20231114_def.xml EX-101.DEF 13329
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrt-20231114_lab.xml EX-101.LAB 21786
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrt-20231114_pre.xml EX-101.PRE 14085
7 EXTRACTED XBRL INSTANCE DOCUMENT d850558d8k_htm.xml XML 4963
Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 231409038
SIC: 2834 Pharmaceutical Preparations